TransMedics Group, Inc. (TMDX)

NGM – Real vaqt narxi. Valyuta: USD

63.93

-0.37 (-0.58%)

Yopilishda: May 12, 2026, 4:00 PM EDT

63.75

-0.18 (-0.28%)

Bozor oldidan: May 13, 2026, 9:08 AM EDT

06.05.2026

TransMedics: Cheaper, But Still Priced For Perfection

TransMedics Group, Inc. remains a Sell as its valuation still bakes in near-perfect execution, despite the stock being nearly 40% cheaper since October. TMDX's valuation implies sustaining some combination of between 9–20% revenue growth and 9–17% free cash flow margins, which remains a high bar given current trends. Growth levers like CHOPS, international expansion, and potential OPO conversion are either hedges, slow-moving, or highly uncertain, making current valuation hard to justify.

06.05.2026

TMDX Dips After Posting Q1 Earnings & Revenue Miss, Margins Fall

TransMedics' Q1 revenues rise 21% on strong OCS demand, but a sharp EPS miss and margin pressure send shares down despite continued logistics growth.

06.05.2026

TransMedics Group, Inc. (TMDX) Q1 2026 Earnings Call Transcript

06.05.2026

TransMedics (TMDX) Reports Q1 Earnings: What Key Metrics Have to Say

While the top- and bottom-line numbers for TransMedics (TMDX) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

05.05.2026

TransMedics (TMDX) Q1 Earnings and Revenues Miss Estimates

TransMedics (TMDX) came out with quarterly earnings of $0.3 per share, missing the Zacks Consensus Estimate of $0.62 per share. This compares to earnings of $0.7 per share a year ago.

05.05.2026

TransMedics Reports First Quarter 2026 Financial Results

ANDOVER, Mass., May 5, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended March 31, 2026.

29.04.2026

TransMedics Group Announces Intent to Create the First Dedicated European Transplant Logistics Network with Strategic Investment in PAD Aviation service GmbH

Proposed strategic investment in Germany-based PAD Aviation, a premier European private aviation operator, intended to lay the foundation for TransMedics to establish a dedicated organ transplantation air logistics network across Europe ANDOVER, Mass., April 29, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that it has entered into a definitive agreement to invest in PAD Aviation, a premier Germany-based private aviation operator.

Videolar

No Data

There is no data to display

Press-relizlar

05.05.2026

TransMedics Reports First Quarter 2026 Financial Results

29.04.2026

TransMedics Group Announces Intent to Create the First Dedicated European Transplant Logistics Network with Strategic Investment in PAD Aviation service GmbH

23.04.2026

TransMedics to Provide Update on Ongoing Clinical Programs at the International Society of Heart and Lung Transplantation 2026 Annual Meeting

Unveils New Controlled Hypothermic Organ Preservation System (CHOPS) to Expand its Product Portfolio and to Facilitate Enrollment in Control Arms of OCS ENHANCE Heart Part B and OCS DENOVO Lung Clinical Trials ANDOVER, Mass., April 23, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, is today providing an update on its ongoing clinical programs at the International Society of Heart and Lung Transplantation (ISHLT) 2026 Annual Meeting in Toronto, Canada.

27.02.2026

TransMedics Provides Additional Information on the Impact of the Release of the Valuation Allowance on Deferred Tax Assets on Previously Reported Fourth Quarter Financial Results

ANDOVER, Mass., Feb. 27, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today issued additional information on the impact of the valuation allowance on deferred tax assets reported in the Company's fourth quarter financial results for the year ended December 31, 2025.

TransMedics Group, Inc. (TMDX)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

TransMedics Group, Inc. (TMDX)

TransMedics: Cheaper, But Still Priced For Perfection

TMDX Dips After Posting Q1 Earnings & Revenue Miss, Margins Fall

TransMedics Group, Inc. (TMDX) Q1 2026 Earnings Call Transcript

TransMedics (TMDX) Reports Q1 Earnings: What Key Metrics Have to Say

TransMedics (TMDX) Q1 Earnings and Revenues Miss Estimates

TransMedics Reports First Quarter 2026 Financial Results

TransMedics Group Announces Intent to Create the First Dedicated European Transplant Logistics Network with Strategic Investment in PAD Aviation service GmbH

Videolar

No Data

Press-relizlar

TransMedics Reports First Quarter 2026 Financial Results

TransMedics Group Announces Intent to Create the First Dedicated European Transplant Logistics Network with Strategic Investment in PAD Aviation service GmbH

TransMedics to Provide Update on Ongoing Clinical Programs at the International Society of Heart and Lung Transplantation 2026 Annual Meeting

TransMedics Provides Additional Information on the Impact of the Release of the Valuation Allowance on Deferred Tax Assets on Previously Reported Fourth Quarter Financial Results

TransMedics: Cheaper, But Still Priced For Perfection

TMDX Dips After Posting Q1 Earnings & Revenue Miss, Margins Fall

TransMedics Group, Inc. (TMDX) Q1 2026 Earnings Call Transcript

TransMedics (TMDX) Reports Q1 Earnings: What Key Metrics Have to Say

TransMedics (TMDX) Q1 Earnings and Revenues Miss Estimates

TransMedics Reports First Quarter 2026 Financial Results

TransMedics Group Announces Intent to Create the First Dedicated European Transplant Logistics Network with Strategic Investment in PAD Aviation service GmbH

Videolar

No Data

Press-relizlar

TransMedics Reports First Quarter 2026 Financial Results

TransMedics Group Announces Intent to Create the First Dedicated European Transplant Logistics Network with Strategic Investment in PAD Aviation service GmbH

TransMedics to Provide Update on Ongoing Clinical Programs at the International Society of Heart and Lung Transplantation 2026 Annual Meeting

TransMedics Provides Additional Information on the Impact of the Release of the Valuation Allowance on Deferred Tax Assets on Previously Reported Fourth Quarter Financial Results

Search stocks

TransMedics Group, Inc. (TMDX)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

TransMedics Group, Inc. (TMDX)

TransMedics: Cheaper, But Still Priced For Perfection

TMDX Dips After Posting Q1 Earnings & Revenue Miss, Margins Fall

TransMedics Group, Inc. (TMDX) Q1 2026 Earnings Call Transcript

TransMedics (TMDX) Reports Q1 Earnings: What Key Metrics Have to Say

TransMedics (TMDX) Q1 Earnings and Revenues Miss Estimates

TransMedics Reports First Quarter 2026 Financial Results

TransMedics Group Announces Intent to Create the First Dedicated European Transplant Logistics Network with Strategic Investment in PAD Aviation service GmbH

Videolar

No Data

Press-relizlar

TransMedics Reports First Quarter 2026 Financial Results

TransMedics Group Announces Intent to Create the First Dedicated European Transplant Logistics Network with Strategic Investment in PAD Aviation service GmbH

TransMedics to Provide Update on Ongoing Clinical Programs at the International Society of Heart and Lung Transplantation 2026 Annual Meeting

TransMedics Provides Additional Information on the Impact of the Release of the Valuation Allowance on Deferred Tax Assets on Previously Reported Fourth Quarter Financial Results

TransMedics: Cheaper, But Still Priced For Perfection

TMDX Dips After Posting Q1 Earnings & Revenue Miss, Margins Fall

TransMedics Group, Inc. (TMDX) Q1 2026 Earnings Call Transcript

TransMedics (TMDX) Reports Q1 Earnings: What Key Metrics Have to Say

TransMedics (TMDX) Q1 Earnings and Revenues Miss Estimates

TransMedics Reports First Quarter 2026 Financial Results

TransMedics Group Announces Intent to Create the First Dedicated European Transplant Logistics Network with Strategic Investment in PAD Aviation service GmbH

Videolar

No Data

Press-relizlar

TransMedics Reports First Quarter 2026 Financial Results

TransMedics Group Announces Intent to Create the First Dedicated European Transplant Logistics Network with Strategic Investment in PAD Aviation service GmbH

TransMedics to Provide Update on Ongoing Clinical Programs at the International Society of Heart and Lung Transplantation 2026 Annual Meeting

TransMedics Provides Additional Information on the Impact of the Release of the Valuation Allowance on Deferred Tax Assets on Previously Reported Fourth Quarter Financial Results